



## Letter to the Editor

### Systemic lupus erythematosus myocarditis and COVID-19 vaccination: Comment



### Miocarditis por lupus eritematoso sistémico y vacunación contra la COVID-19: comentario

Dear Editor,

We read with great interest the publication *Systemic lupus erythematosus myocarditis after COVID-19*<sup>1</sup> by Sogbe et al. describing a 72-year-old woman with pleuritic chest pain one week after receiving the third dose of BNT162b2 mRNA vaccine.<sup>1</sup> Serological tests for cardiotropic infections were negative, but autoimmune screening revealed positive results for antinuclear antibodies at 1:160 dilution, anti-dsDNA, and anti-histone antibodies.<sup>1</sup> Sogbe et al. suggested a diagnosis of systemic lupus erythematosus with cardiac affection.<sup>1</sup> According to Sogbe et al., this is the first case report of lupus myocarditis after COVID-19 vaccination.<sup>1</sup>

It is understandable that the COVID-19 vaccine may cause a rheumatological problem. However, any possible background disease and co-morbidity must be ruled out. It is impossible to rule out pre- or post-vaccination immunological/rheumatological problems without laboratory investigation data. This is a clinical

problem that might go unnoticed as a side effect of vaccination due to the presence of a confounding factor.<sup>2</sup> Last, but no less important, silent and asymptomatic infection with COVID-19 is possible and may develop during or after vaccination.<sup>3</sup> COVID-19 is another potential contributor to lupus myocarditis.

## References

1. Sogbe M, Blanco-Di Matteo A, Di Frisco IM, Bastidas JF, Salterain N, Gavira JJ. Systemic lupus erythematosus myocarditis after COVID-19 vaccination. *Reumatol Clin (Engl Ed)*. 2023;19:114–6. <http://dx.doi.org/10.1016/j.reuma.2022.06.006>.
2. Sookaromdee P, Wiwanitkit V. Adverse events following immunisation (AEFI) after first dose of COVID-19 vaccine. *Med J Armed Forces India*. 2022;78:113–4.
3. Joob B, Wiwanitkit V. Letter to the Editor: Coronavirus Disease 2019 (COVID-19), Infectivity, and the Incubation Period. *J Prev Med Public Health*. 2020;53:70.

Amnuay Kleebayoon,<sup>a,\*</sup> Viroj Wiwanitkit<sup>b,c</sup>

<sup>a</sup> Private Academic Consultant, Samraong, Cambodia

<sup>b</sup> Joseph Ayobabalola University, Ikeji-Arakeji, Nigeria

<sup>c</sup> Chandigarh University, Punjab, India

\* Corresponding author.

E-mail address: [amnuaykleebai@gmail.com](mailto:amnuaykleebai@gmail.com) (A. Kleebayoon).